Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Merck's HIV combo treatment meets efficacy bar in phase 3 trials
Two phase 3 studies assessing a combo of Merck's approved doravirine and investigational islatravir met their primary efficacy goals.
Zoey Becker
Dec 19, 2024 11:54am
AI-powered Terray is teaming up with Gilead in a fresh R&D pact
Dec 17, 2024 8:00am
Gilead's O'Day relishes reunion as Berger agrees to leave Sanofi
Dec 13, 2024 5:20am
Gilead advances ADC dreams with potential $465M deal
Dec 3, 2024 10:54am
Gilead buys HIV vaccine from biotech following clinical collab
Nov 25, 2024 10:30am
Gilead to lay off 72 staffers, shutter Seattle R&D office
Nov 14, 2024 1:09pm
